Advertisement

Phase I trial of oral talactoferrin alfa in refractory solid tumors

  • Teresa G. HayesEmail author
  • Gerald F. Falchook
  • Gauri R. Varadhachary
  • Dori P. Smith
  • Lisa D. Davis
  • Hari M. Dhingra
  • Benjamin P. Hayes
  • Atul Varadhachary
Phase I Studies

Summary

Background: Lactoferrin is an iron-binding glycoprotein first identified in breast milk as a protein product of mammary epithelial cells. Its immunomodulatory functions include activation of NK and lymphokine-activated killer cells and enhancement of PMN and macrophage cytotoxicity. Studies in animal models have shown promising anti-cancer activity. The purpose of the present study was to evaluate the safety and tolerability of talactoferrin alfa (talactoferrin; TLF) in humans, as well as pharmacokinetics and pharmacodynamics. Methods: Ten adult patients with progressive advanced solid tumors who had failed conventional chemotherapy were administered oral TLF at doses from 1.5 to 9 g/day, using a 2 weeks on, 2 weeks off schedule. Patients were evaluated for drug toxicity, tumor growth rate, talactoferrin pharmacokinetics and cytokine markers. Results: Talactoferrin was very well tolerated. No hematological, hepatic, or renal toxicities were reported. A single patient had Grade 2 diarrhea, and there were no Grade 3 or 4 toxicities. Following oral administration, significant levels of talactoferrin were undetectable in circulation, but a statistically significant increase in circulating IL-18, a pharmacodynamic indicator of talactoferrin activity, was observed. Of the eight patients who were radiologically evaluable, five (63%) had stable disease by RECIST criteria two months after start of therapy, including one patient with a minor response. Seven patients (88%) had a decrease in their tumor growth rate. The three patients with non-small cell lung cancer (NSCLC) all survived for at least one year following the start of talactoferrin monotherapy. Conclusions: Talactoferrin is a promising, well-tolerated new agent that should be evaluated further in patients with refractory metastatic cancer.

Key Words

talactoferrin nonsmall cell lung cancer refractory cancer 

References

  1. 1.
    Kanyshkova TG, Buneva VN, Nevinsky GA: Lactoferrin and its biological functions. Biochemistry 66: 1–7, 2001PubMedGoogle Scholar
  2. 2.
    Wright DG, Gallin JI: Secretory responses of human neutrophils: exocytosis of specific (secondary) granules by human neutrophils during adherence in vitro and during exudation in vivo. J Immunol 23:285–294, 1979Google Scholar
  3. 3.
    Vorland LH: Lactoferrin: a multifunctional glycoprotein. APMIS 107: 971–981, 1999PubMedCrossRefGoogle Scholar
  4. 4.
    Bellamy W, Takase M, Wakabayashi H, et al.: Antibacterial spectrum of lactoferrin B, a potent bactericidal peptide derived from the N-terminal region of bovine lactoferrin. J Appl Bacteriol 73: 472–479, 1992PubMedGoogle Scholar
  5. 5.
    Horwitz DA, Bakke AC, Abo W, et al.: Monocyte and NK cell cytotoxic activity in human adherent cell preparations: discriminating effects of interferon and lactoferrin. J Immunol 132: 2370–2374, 1984PubMedGoogle Scholar
  6. 6.
    Tsuda H, Sekine K, Fujita K, Ligo M: Cancer prevention by bovine lactoferrin and underlying mechanisms–a review of experimental and clinical studies. Biochem Cell Biol 80: 131–136, 2002CrossRefPubMedGoogle Scholar
  7. 7.
    Gahr M, Speer CP, Damerau B, et al.: Influence of lactoferrin on the function of human polymorphonuclear leukocytes and monocytes. J Leukocyte Biol 49: 427–433, 1991PubMedGoogle Scholar
  8. 8.
    Ward PP, Piddington CS, Cunningham GA, et al.: A system for production of commercial quantities of human lactoferrin: a broad spectrum natural antibiotic. Biotechnology 13: 498–503, 1995CrossRefPubMedGoogle Scholar
  9. 9.
    Varadhachary A, Petrak K, Wolf JS, et al.: Recombinant human lactoferrin: a novel oral anti-cancer drug. Proc Ann Meeting Am Soc Clin Oncol 22: 233, 2003 (abstr)Google Scholar
  10. 10.
    Varadhachary A, Wolf JS, Petrak K, et al.: Oral lactoferrin inhibits growth of established tumors and potentiates conventional chemotherapy. Int J Cancer 111: 398–403, 2004CrossRefPubMedGoogle Scholar
  11. 11.
    Kawakami H, Lonnerdal B: Isolation and function of a receptor for human lactoferrin in human fetal intestinal brush-border membranes. Am J Physiol 261: G841–G846, 1991PubMedGoogle Scholar
  12. 12.
    Hu WL, Mazurier J, Sawatzki G, et al.: Lactotransferrin receptor of mouse small-intestinal brush border: binding characteristics of membrane-bound and triton X-100-solubilized forms. Biochem J 249: 435–441, 1988PubMedGoogle Scholar
  13. 13.
    Therasse P, Arbuck SG, Eisenhauer EA, et al.: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205–216, 2000CrossRefPubMedGoogle Scholar
  14. 14.
    Mojaverian P, Robbins-Weilert D, Gbenado S, et al.: Single and Multiple Dose Safety, Tolerability and Pharmacokinetics (PK) of Oral Recombinant Lactoferrin (TLF) in Healthy Subjects. Proc Am Ass Immun, 2003Google Scholar
  15. 15.
    Ishii K, Takamura N, Shinohara M, et al.: Long-term follow-up of chronic hepatitis C patients treated with oral lactoferrin for 12 months. Hepatol Res 25(3): 226–233, 2003CrossRefPubMedGoogle Scholar
  16. 16.
    Shepherd FA, Dancey J, Ramlau R, et al.: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 19: 2108–2109, 2000Google Scholar
  17. 17.
    Troost FJ, Saris WH, Brummer RJ: Recombinant human lactoferrin ingestion attenuates indomethacin-induced enteropathy in vivo in healthy volunteers. Eur J Clin Nutr 57(12): 1579–1585, 2003CrossRefPubMedGoogle Scholar
  18. 18.
    Mick R, Crowley JJ, Carroll RJ: Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint. Control Clin Trials 21(4): 343–359, 2000CrossRefPubMedGoogle Scholar
  19. 19.
    Retsky MW, Swartzendruber DE, Wardwell RH, et al.: Is Gompertzian or exponential kinetics a valid description of individual human cancer growth? Med Hypotheses 33: 95–106, 1990CrossRefPubMedGoogle Scholar
  20. 20.
    Bru A, Albertos S, Luis Subiza J, et al.: The universal dynamics of tumor growth. Biophys J 85: 2948–2961, 2003PubMedCrossRefGoogle Scholar
  21. 21.
    Cellerino R, Tummarello D, Guidi F, et al.: A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small cell lung cancer. J Clin Oncol 9: 1453–1461, 1991PubMedGoogle Scholar
  22. 22.
    Woods RL, Williams CJ, Levi J, et al.: A randomized trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. Br J Cancer 61: 608–611, 1990PubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2005

Authors and Affiliations

  • Teresa G. Hayes
    • 1
    • 2
    Email author
  • Gerald F. Falchook
    • 1
  • Gauri R. Varadhachary
    • 1
  • Dori P. Smith
    • 1
  • Lisa D. Davis
    • 1
  • Hari M. Dhingra
    • 1
  • Benjamin P. Hayes
    • 1
  • Atul Varadhachary
    • 1
  1. 1.Michael E. DeBakey VA Medical Center and Baylor College of MedicineHoustonUSA
  2. 2.VA 111H, Michael E. DeBakey VA Medical CenterHoustonUSA

Personalised recommendations